GSTM1 and Iron deficiency anemia: A recent, randomized clinical trial performed in patients with ND-CKD and iron-deficiency anemia showed that Sucrosomial iron was non-inferior to a typical dosing strategy of IV iron gluconate with regard to the primary efficacy end point, the mean change in Hb values from baseline to the end of treatment [8].